Reported 13 shares, down 1 (7.1%) from the prior quarter.
Reported value -5.3%; share count -7.1% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2025-03-31 | 1728 |
| 2025-06-30 | 1591 |
| 2025-09-30 | 433 |
| 2025-12-31 | 270 |
| 2026-03-31 | 19 |
| 2026-06-30 | 18 |
| 2026-09-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Reduced | 0 | -13 (-100.0%) | 0 | $0 | 2026-10-22 | |
| Q2 2026 | Reduced | 13 | -1 (-7.1%) | < 0.01% | $18 | 2026-07-23 | |
| Q1 2026 | Reduced | 14 | -155 (-91.7%) | < 0.01% | $19 | 2026-04-28 | |
| Q4 2025 | Unchanged | 169 | 0 (0.0%) | < 0.01% | $270 | 2026-02-03 | |
| Q3 2025 | Reduced | 169 | -710 (-80.8%) | < 0.01% | $433 | 2025-11-05 | |
| Q2 2025 | Added | 879 | +28 (3.3%) | < 0.01% | $1,591 | 2025-08-08 | |
| Q1 2025 | New | 851 | +851 (0.0%) | < 0.01% | $1,728 | 2025-05-02 |
Who else reported the position
47 managers reported BIOXCEL THERAPEUTICS INC for Q2 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | Added | 2,114,710 | +177,950 | < 0.01% | $2,981,741 | 4 qtrs |
| OAKTREE CAPITAL MANAGEMENT LP | Added | 1,380,248 | +1,139,060 | 0.03% | $1,946,150 | 5 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 919,545 | +712,206 | < 0.01% | $1,296,558 | 2 qtrs |
| Oaktree Fund Advisors LLC | Added | 245,585 | +202,672 | 0.6% | $346,274 | 5 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 242,251 | +12,083 | < 0.01% | $341,911 | 6 qtrs |
| BlackRock Inc | Added | 179,433 | +95,151 | < 0.01% | $253,001 | 6 qtrs |
| UBS Group AG | Added | 158,065 | +105,277 | < 0.01% | $222,871 | 6 qtrs |
| CITADEL ADVISORS LLC | New | 149,220 | +149,220 | < 0.01% | $210,400 | 1 qtr |
| VANGUARD FIDUCIARY TRUST CO | Added | 136,937 | +52,016 | < 0.01% | $193,081 | 2 qtrs |
| STATE STREET CORPORATION | Unchanged | 92,118 | 0 | < 0.01% | $129,886 | 4 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2026
- Filed
- July 23, 2026
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 13
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.